Showing 1682 results
-
Press release /Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[…
-
Press release /New x-ray assessment data, from a sub-study, showed no progression of joint structural damage in the majority of patients with psoriatic arthritis over two years[1] Psoriatic arthritis patients on…
-
Press release /Farydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1] Farydak prolonged median…
-
Story /Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.
-
Press release /Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of…
-
Press release /Solides Wachstum (kWk) beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie[2] im Gesamtjahr Der Nettoumsatz steigt um 5% (kWk), das operative Kernergebnis wächst um 10% (kWk) Die…
-
Ad hoc release /Basel, May 1, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") applicable to…
-
Press release /A sub-study showed up to 80% of ankylosing spondylitis (AS) patients treated with Cosentyx had no radiographic progression in the spine over two years[1] Cosentyx demonstrated a sustained…
-
Press release /Sandoz Pharmaceuticals AG wurde offiziell vom Top Employers Institute für ihr hervorragendes Mitarbeiterangebot in der Schweiz ausgezeichnet Die jährliche internationale Forschungstätigkeit des…
-
Press release /First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and…